Jeremy Grantham Kiniksa Pharmaceuticals, Ltd. Transaction History
Grantham, Mayo, Van Otterloo & Co. LLC
- $29.8 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding KNSA
# of Institutions
8Shares Held
1.95MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$29.9 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$4 Million2.82% of portfolio
-
Harbor Capital Advisors, Inc.98.1KShares$1.94 Million0.08% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$779,4530.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$592,2000.51% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $680M
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...